The differential results reflect the diversity of approaches used in previous studies to assess the TTR alterations in the CSF of MS patients and shows the relevance of using methodologies that identify posttranslational modifications of the protein, or those that can distinguish different proteoforms, such as 2D-PAGE. This evidence concerns the gene TTR and myeloid sarcoma.